Merus raises €31m as J&J third corporate VC to invest
This article was originally published in Scrip
Merus of the Netherlands has added to its series B round with a further €31m, bringing the total round to €47.6m. Johnson & Johnson Development Corporation (JJDC) joined as a new investor, and existing investors Novartis Venture Fund, Pfizer Venture Investments, Bay City Capital, LSP (Life Sciences Partners) and Aglaia Oncology Fund also participated.
You may also be interested in...
The US biotech is paying $200m up front in cash and equity investment for the ability to use Merus’ bispecific technology platform in up to 11 programs, which could move beyond cancer and include novel targets and biology. Potential earn-outs under the deal could reach nearly $3bn.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.